Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.

Détails

ID Serval
serval:BIB_DB6A51490542
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.
Périodique
Blood
Auteur(s)
Bossard C., Dobay M.P., Parrens M., Lamant L., Missiaglia E., Haioun C., Martin A., Fabiani B., Delarue R., Tournilhac O., Delorenzi M., Gaulard P., de Leval L.
ISSN
1528-0020 (Electronic)
ISSN-L
0006-4971
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
124
Numéro
19
Pages
2983-2986
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish
Résumé
The extended use of brentuximab-vedotin was reported for CD30(+) nonanaplastic peripheral T-cell lymphomas (PTCLs) with promising efficacy. CD30 status assessment is thus a critical factor for therapeutic decision, but the reliability of immunohistochemistry (IHC) in evaluating its expression remains to be defined. This prompted us to investigate the correlation between semiquantitative CD30 protein assessment by IHC and messenger RNA (mRNA) assessment by microarrays in a cohort of 376 noncutaneous PTCLs representative of the main entities. By IHC, CD30 expression was heterogeneous across and within entities and significantly associated with large tumor cell size. In addition to 100% anaplastic large-cell lymphomas, 57% of other PTCL entities were CD30-positive at a 5% threshold. CD30 protein expression was highly correlated to mRNA levels. mRNA levels were bimodal, separating high from low CD30-expressing PTCL cases. We conclude that IHC is a valuable tool in clinical practice to assess CD30 expression in PTCLs.
Pubmed
Web of science
Open Access
Oui
Création de la notice
18/09/2014 11:34
Dernière modification de la notice
09/05/2019 2:08
Données d'usage